According to KEGG pathway analysis, the metabolic pathways and metabolites enriched in the pathway were identified (Fig. 5E,F), thus broadening our knowledge of metformin’s impact on the metabolism of STK11 mutant NSCLC, and providing an opportunity for us to explore novel therapeutic strategy by altering metabolites in the TME. The gene discussed is STK11; the disease is non-small cell lung carcinoma.